G1 Therapeutics Announces Retrospective Analysis Of Pooled Results From Three Studies Shows COSELA Reduced Use Of Supportive Care Interventions In Extensive Stage Small Cell Lung Cancer Patients Who Receive The Drug Prior To Chemotherapy
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced results from a retrospective analysis of the pooled results of three randomized trilaciclib studies showing that
G1 Therapeutics Announces Permanent J-Code From Centers For Medicare And Medicaid Services
G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that the permanent J-code for COSELA™ (trilaciclib) that was issued in July 2021 by the Centers for Medicare & Medicaid
10 Biggest Price Target Changes For Thursday
Jefferies raised Perrigo Company plc (NYSE: PRGO) price target from $45 to $63. Perrigo shares jumped 13.3% to $49.27 in pre-market trading.
JP Morgan Downgrades G1 Therapeutics to Neutral, Lowers Price Target to $20
JP Morgan analyst Anupam Rama downgrades G1 Therapeutics (NASDAQ:GTHX) from Overweight to Neutral and lowers the price target from $24 to $20.
G1 Therapeutics Announces New Supplemental COSELA Sales Force; Co. Will Hire And Train A 15-Person Oncology Sales Force To Supplement The Boehringer Ingelheim Oncology Commercial Team
G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that it will hire and train a 15-person oncology sales force to supplement the Boehringer Ingelheim oncology commercial team. The
Return on Capital Employed Overview: G1 Therapeutics
Pulled from Benzinga Pro data G1 Therapeutics (NASDAQ:GTHX) reported Q2 sales of $6.60 million. Earnings fell to a loss of $38.19 million, resulting in a 49.57% decrease from last quarter.
G1 Therapeutics Q2 EPS $(0.94) Beats $(0.97) Estimate, Sales $6.60M Beat $2.59M Estimate
G1 Therapeutics (NASDAQ:GTHX) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(0.97) by 3.09 percent. This is a 13.25 percent decrease over losses of $(0.83) per share from
The Daily Biotech Pulse: Pfizer’s Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)